Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Status:
Withdrawn
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The size of the acute myocardial infarction (AMI) is related to ischemia and injury induced
by tissue reperfusion. These reperfusion's injuries can be reduced by injection of
cyclosporin A (CsA) at the time of reperfusion. This post-conditioning reduces the final
infarct size 20 to 40%. This has been demonstrated in STEMI patients non-complicated by
cardiogenic shock. Early revascularization in the AMI complicated by cardiogenic shock
improves short-term and long term survival by reducing the size of the myocardial infarction.
The hypothesis of this study is that the administration of Cyclosporin A to these patients,
in addition to mechanical reperfusion, is likely to reduce the severity of the multi-organ
failure associated with the cardiogenic shock and improve clinical outcome.